Eur Urol. 2012 Mar;61(3):624-5.

Re: Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the reduction by dutasteride of prostate cancer events trial.

Oelke M.

Source

Department of Urology, Hannover Medical School, Hannover, Germany. oelke.matthias@mh-hannover.de

Comment on

Urology. 2011 Sep;78(3):641-6.

PMID:: 22289977; [PubMed]

Publication Types

Comment

LinkOut - more resources

Full Text Sources

Supplemental Content

Save items

Related citations in PubMed

Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. [Urology. 2011]
Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, Rittmaster RS. Urology. 2011 Sep; 78(3):641-6. Epub 2011 Jul 20.
Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. [Urology. 2004]
Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS. Urology. 2004 Sep; 64(3):537-41; discussion 542-3.
Effect of dutasteride on the risk of prostate cancer. [N Engl J Med. 2010]
Effect of dutasteride on the risk of prostate cancer.
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, et al. N Engl J Med. 2010 Apr 1; 362(13):1192-202.
Review Dutasteride: a review of its use in the management of prostate disorders. [Drugs. 2008]
Review Dutasteride: a review of its use in the management of prostate disorders.
Keam SJ, Scott LJ. Drugs. 2008; 68(4):463-85.
Review Chemoprevention using dutasteride: the REDUCE trial. [Curr Opin Urol. 2005]
Review Chemoprevention using dutasteride: the REDUCE trial.
Gomella LG. Curr Opin Urol. 2005 Jan; 15(1):29-32.

See reviews... See all...

Recent activity

Clear Turn Off Turn On

Re: Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated...
Re: Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the reduction by dutasteride of prostate cancer events trial.
Eur Urol. 2012 Mar ;61(3):624-5.

PubMed
Susceptibility to pattern glare following stroke.
Susceptibility to pattern glare following stroke.
J Neurol. 2012 Jan 31. [Epub ahead of print]

PubMed
Natalizumab treatment of multiple sclerosis in Spain: results of an extensive ob...
Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study.
J Neurol. 2012 Jan 31. [Epub ahead of print]

PubMed
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative ...
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.
Blood. 2012 Mar 22 ;119(12):2956-9. Epub 2012 Jan 30 .

PubMed
[Unexpected link between Huntington disease and Rett syndrome].
[Unexpected link between Huntington disease and Rett syndrome].
Med Sci (Paris). 2012 Jan ;28(1):44-6. Epub 2012 Jan 27 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Re: Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the reduction by dutasteride of prostate cancer events trial.

Source

Comment on

Publication Types

Publication Types

LinkOut - more resources

Full Text Sources

Supplemental Content

Save items

Related citations in PubMed

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information